Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

Clicks: 561
ID: 117567
1970
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In this rural African setting, pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival. Pneumococcal conjugate vaccines should be made available to African infants.
Reference Key
ft1970lancetefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cutts FT;Zaman SM;Enwere G;Jaffar S;Levine OS;Okoko JB;Oluwalana C;Vaughan A;Obaro SK;Leach A;McAdam KP;Biney E;Saaka M;Onwuchekwa U;Yallop F;Pierce NF;Greenwood BM;Adegbola RA; ;;
Journal Lancet (London, England)
Year 1970
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/15794968
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't u.s. gov't non-p.h.s. female male Child Infant P.H.S. preschool Clinical Trial Randomized Controlled Trial Multicenter Study Incidence pneumonia vaccines pneumococcal infections / diagnosis immunization schedule pneumococcal infections / prevention & control* pneumococcal / diagnosis pneumococcal / epidemiology conjugate f t cutts pmid:15794968 doi:10.1016/s0140-6736(05)71876-6 s m a zaman gambian pneumococcal vaccine trial group gambia / epidemiology pneumococcal infections / epidemiology pneumococcal vaccines / administration & dosage* pneumococcal vaccines / adverse effects pneumococcal / prevention & control*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.